ES2122098T3 - Antagonistas del nmda. - Google Patents

Antagonistas del nmda.

Info

Publication number
ES2122098T3
ES2122098T3 ES94110261T ES94110261T ES2122098T3 ES 2122098 T3 ES2122098 T3 ES 2122098T3 ES 94110261 T ES94110261 T ES 94110261T ES 94110261 T ES94110261 T ES 94110261T ES 2122098 T3 ES2122098 T3 ES 2122098T3
Authority
ES
Spain
Prior art keywords
antagonists
halo
formula
nmda
epilepsy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94110261T
Other languages
English (en)
Inventor
Michael G Palfreyman
Francesco G Salituro
Ian A Mcdonald
Robert Schwarcz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2122098T3 publication Critical patent/ES2122098T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/42—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton with carboxyl groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C213/00—Preparation of compounds containing amino and hydroxy, amino and etherified hydroxy or amino and esterified hydroxy groups bound to the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

LA PRESENTE INVENCION VA DIRIGIDA A UN NUEVO USO PARA UN GRUPO DE 6-HALO-TRIPTOFANO DE FORMULA (IA) Y 4-HALO-QUINURENINA DERIVADA DE FORMULA (IB) PARA LA PREPARACION DE UNA COMPOSICION FARMACEUTICA COMO ANTAGONISTAS EXCITADORES DE AMINO ACIDO, PARA USO EN EL TRATAMIENTO DE ESTADOS DE ENFERMEDAD TAL COMO EPILEPSIA, ANSIEDAD Y ATAQUE APOPLETICO.
ES94110261T 1991-02-28 1992-02-24 Antagonistas del nmda. Expired - Lifetime ES2122098T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US66267091A 1991-02-28 1991-02-28

Publications (1)

Publication Number Publication Date
ES2122098T3 true ES2122098T3 (es) 1998-12-16

Family

ID=24658685

Family Applications (2)

Application Number Title Priority Date Filing Date
ES92103066T Expired - Lifetime ES2069921T3 (es) 1991-02-28 1992-02-24 Antagonistas del nmda.
ES94110261T Expired - Lifetime ES2122098T3 (es) 1991-02-28 1992-02-24 Antagonistas del nmda.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES92103066T Expired - Lifetime ES2069921T3 (es) 1991-02-28 1992-02-24 Antagonistas del nmda.

Country Status (15)

Country Link
EP (2) EP0501378B1 (es)
JP (1) JP3168566B2 (es)
KR (2) KR100237264B1 (es)
AT (2) ATE168989T1 (es)
AU (2) AU643365B2 (es)
CA (1) CA2061836C (es)
DE (2) DE69201141T2 (es)
DK (2) DK0501378T3 (es)
ES (2) ES2069921T3 (es)
FI (1) FI920880A (es)
GR (1) GR3015130T3 (es)
HU (1) HU213214B (es)
IE (2) IE65728B1 (es)
NO (1) NO178727C (es)
NZ (1) NZ241718A (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69224069T2 (de) * 1991-09-09 1998-07-02 Warner-Lambert Co., Ann Arbor, Mich. Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
US5318985A (en) * 1991-12-20 1994-06-07 Merrell Dow Pharmaceuticals Inc. Potentiation of NMDA antagonists
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
US5519055A (en) * 1993-08-06 1996-05-21 University Of Maryland At Baltimore Substituted kynurenines and process for their preparation
US5786508A (en) * 1994-07-15 1998-07-28 Pharmacia & Upjohn S.P.A. Substituted kynurenines and process for their preparation
GB9521486D0 (en) * 1995-10-20 1995-12-20 Pharmacia Spa Fluoro-substituted benzoylpropionic acid derivatives
SE9901237D0 (sv) * 1999-04-06 1999-04-06 Astra Ab Novel use
EP1964835A1 (en) * 2007-02-28 2008-09-03 Centre National de la Recherche Scientifique Derivatives of psammaplin A, a method for their synthesis and their use for the prevention or treatment of cancer
KR101308507B1 (ko) * 2011-07-07 2013-09-17 (주)비알뷰티플레볼루션 트립토판을 함유하는 여드름 치료제 및 피지분비 억제제, 및 이를 포함하는 광역학적 치료용 키트
WO2017065899A1 (en) * 2015-10-16 2017-04-20 Auspex Pharmaceuticals, Inc. Deuterated chlorokynurenines for the treatment of neuropsychiatric disorders
EP3427729A1 (en) * 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
JP7431163B2 (ja) 2018-02-09 2024-02-14 ヴィスタゲン セラピューティクス、インコーポレイテッド ４－クロロキヌレニンおよび中間体の合成

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1179866B (it) * 1984-12-12 1987-09-16 Rotta Research Lab Derivati del triptofano farmaceuticamente attivi e composizioni farmaceutiche che li contengono
IT1206078B (it) * 1987-06-03 1989-04-14 Polifarma Spa Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
IT1237472B (it) * 1989-10-04 1993-06-07 Polifarma Spa Derivati di acido 3-indolpiruvico, loro procedimento di produzione ed impiego terapeutico.
DE19502075A1 (de) * 1995-01-24 1996-07-25 Grohe Armaturen Friedrich Auslaufarmatur mit Befestigungseinrichtung

Also Published As

Publication number Publication date
HU9200658D0 (en) 1992-05-28
ATE116969T1 (de) 1995-01-15
DE69226447T2 (de) 1999-04-22
DE69226447D1 (de) 1998-09-03
IE920631A1 (en) 1992-09-09
NO178727C (no) 1996-05-22
AU4497593A (en) 1993-11-18
NO178727B (no) 1996-02-12
FI920880A (fi) 1992-08-29
IE80774B1 (en) 1999-02-10
KR100237264B1 (ko) 2000-02-01
DE69201141T2 (de) 1995-05-11
CA2061836C (en) 2006-05-02
CA2061836A1 (en) 1992-08-29
NO920784D0 (no) 1992-02-27
KR100261933B1 (ko) 2000-07-15
AU1114492A (en) 1992-09-03
NO920784L (no) 1992-08-31
JP3168566B2 (ja) 2001-05-21
GR3015130T3 (en) 1995-05-31
ATE168989T1 (de) 1998-08-15
IE65728B1 (en) 1995-11-15
ES2069921T3 (es) 1995-05-16
DE69201141D1 (de) 1995-02-23
EP0501378A1 (en) 1992-09-02
NZ241718A (en) 1994-07-26
HU213214B (en) 1997-03-28
DK0624569T3 (da) 1998-10-26
AU656278B2 (en) 1995-01-27
EP0624569B1 (en) 1998-07-29
DK0501378T3 (da) 1995-03-20
JPH0586027A (ja) 1993-04-06
EP0501378B1 (en) 1995-01-11
AU643365B2 (en) 1993-11-11
KR920016418A (ko) 1992-09-24
EP0624569A1 (en) 1994-11-17
FI920880A0 (fi) 1992-02-27
HUT67033A (en) 1995-01-30

Similar Documents

Publication Publication Date Title
EA200100524A1 (ru) Амиды антраниловой кислоты и их применение в качестве лекарственных средств
ATE381537T1 (de) Formanilid-derivative als beta2-adrenorezeptor- agonisten
DE60220887D1 (de) Agonisten von beta-adrenorezeptoren
AR009052A1 (es) Tienopirimidinas, un procedimiento para su preparacion, empleo de las mismas para preparar un medicamento, preparaciones farmaceuticas que lascontienen y un procedimiento para obtener estas preparaciones farmaceuticas
ES2122098T3 (es) Antagonistas del nmda.
DE69223914D1 (de) 4-substituierte-2-Deoxy-2,3-Didehydro Alpha-D-Neuraminsäure antivirale Derivate
EA200500377A1 (ru) Пиразольные производные как ингибиторы трансформирующего фактора роста (tgf)
CY1119257T1 (el) Θεραπεια του νευροπαθητικου πονου με ανταγωνιστες υποδοχεα δεξτρομεθορφανης n-meθυλ-d-ασπαρτικων (nmda)
ES2051834T3 (es) El uso de tetrahidrobenzeno(c,d)indol-6 carboxamidas para la preparacion de un medicamento para el tratamiento de la ansiedad.
ES2082882T3 (es) Procedimiento para la fabricacion de derivados de acidos-3-amino-2-(het)aroil-acrilicos.
IT1307786B1 (it) Analoghi di ceramidi, processo per la loro preparazione e loro usocome antitumorali.
DK526087D0 (da) Antikonvulsive aminosyrederivater
AR030945A1 (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso
ES2062214T3 (es) Derivados de aminooligohidroxi inhibidores de renina.
FR2835253B1 (fr) Composes, en particulier de derives urees ou esters de l'acide haloacetamidobenzoique et leur utilisation pour le traitement de maladies parasitaires
UY27475A1 (es) Amidas de ácido piperazinciclohexanocarboxílico sustituidas y su utilización
ATE402178T1 (de) Substituierte 5,6,6a,11b-tetrahydro-7-oxa-5-aza- benzoäcüfluoren-6-carbonsäurederivate als nmda- antagonisten
GT199100061A (es) Derivados de acido acetico
EA200300782A1 (ru) Пролекарства возбуждающих аминокислот
RU94017664A (ru) Соединения, используемые в качестве антагонистов 5-нт-рецепторов, способ получения, фармацевтическая композиция
DOP2001000245A (es) Amidas de acido fenilciclohexanocarboxilico sustituido y su uso.
MY135855A (en) "pyrrolopyrimidinone derivatives, process of preparation and use"

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 624569

Country of ref document: ES